Skip to main content

Table 1 Association between the CNA status for the CDKN2A/ARF/CDKN2B locus and early response to treatment as assessed by the MRD levels detected at the end of induction therapy

From: Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia

CDN2A/ARF/CDKN2B gene status MRD ≤ 0.1% P value MRD ≤ 0.01% P value
CDKN2A/ARF
 Bi or mono-allelic deletion (n = 30) 27 (90) 0.04 22 (73) 0.03
 No deletion (n = 30) 17 (68) 11 (44)
CDKN2B
 Bi or mono-allelic deletion (n = 27) 24 (89) 0.10 19 (70) 0.12
 No deletion (n = 28) 20 (71) 14 (50)
CDKN2A/ARF and/or CDKN2B
 Bi or mono-allelic deletion (n = 32) 29 (91) 0.02 24 (75) 0.007
 No deletion (n = 23) 15 (65) 9 (39)
  1. Results expressed as number of cases (percentage)